Results 221 to 230 of about 108,172,160 (276)

Mechanisms behind elevated serum levels of plasminogen activator inhibitor-1 in frontotemporal lobar degeneration. [PDF]

Neural Regen Res
Angelucci F, Hort J.
europepmc   +1 more source

Liver steatosis is positively associated with plasminogen activator inhibitor-1 in apparently healthy individuals with overweight and obesity: A FibroScan-Based Cross-Sectional study. [PDF]

J Transl Med
Lisco G, Guido D, Cerabino N, Di Chito M, Donvito R, Bonfiglio C, Shahini E, Zappimbulso M, Randazzo C, Barletta D, Stabile D, Ancona A, Coletta S, Pesole PL, Giannelli G, De Pergola G.   +15 more
europepmc   +1 more source

Dementia with Lewy Bodies (DLB), Parkinson's Disease (PD), and Multiple System Atrophy (MSA) Are Synucleopathies Characterized by Increased Serum Levels of Plasminogen Activator Inhibitor‑1 (PAI-1). [PDF]

ACS Omega
Angelucci F, Nedelska Z, Napravnikova Manová B, Katonová A, Jurášová V, Svetlikova D, Vyhnálek M, Hort J.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Plasminogen Activator Inhibitor-1

Current Medicinal Chemistry, 2004
Plasminogen activator inhibitor-1 (PAI-1) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Consequently, PAI-1 plays an important role in cardiovascular diseases (mainly through inhibition of t-PA) and in cell migration and tumor development (mainly through ...
Ann, Gils, Paul J, Declerck
openaire   +2 more sources

Plasminogen Activator Inhibitor-1 in Aging

Seminars in Thrombosis and Hemostasis, 2014
Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissolution of fibrin and also inhibit ...
Koji, Yamamoto, Kyosuke, Takeshita, Hidehiko, Saito   +2 more
openaire   +2 more sources

Plasminogen Activator Inhibitor-1 and Restenosis

Current Drug Targets, 2007
Despite the introduction of drug-eluting stents restenosis remains an important clinical problem. In this review we examine the role of plasminogen activator inhibitor-1 (PAI-1) in controlling restenosis after balloon angioplasty and stent implantation.
Nadish, Garg, William P, Fay
openaire   +2 more sources

Plasminogen Activator Inhibitor-1 [PDF]

Circulation, 2013
Hypertension is the most common reversible risk factor for stroke, myocardial infarction, and heart failure, affecting >60 million individuals in the United State alone and 1 billion globally.1 According to the World Health Organization, hypertension is now the leading cause of preventable death worldwide.2 Importantly, the prevalence and complications
Daniel I Simon, Norman M Simon
exaly   +3 more sources

Neutralization by Plasminogen Activator Inhibitor-1 of Mutants of Tissue Plasminogen Activator

Enzyme, 2017
Deletion mutants of human tissue plasminogen activator (tPA) were expressed in Chinese hamster ovary cells. These cells had been transfected with genes that encoded tPA but included restriction sites that allowed the deletion of DNA encoding specific structural domains of the tPA molecule’s heavy chain.
P W, Bergum, L A, Erickson
openaire   +2 more sources

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Stroke Patients

Stroke, 1996
Background and Purpose Abnormal endogenous fibrinolytic activity may be a risk factor for stroke. Since the possible variation of tissue-type plasminogen activator (TPA) antigen and plasminogen activator inhibitor-1 (PAI-1) antigen concentrations over time after stroke has been rarely studied, it was examined in plasma from ...
A, Lindgren, C, Lindoff, B, Norrving, B, Astedt, B B, Johansson   +4 more
openaire   +2 more sources